202 related articles for article (PubMed ID: 30790641)
1. Recent advances in the development of Mcl-1 inhibitors for cancer therapy.
Hird AW; Tron AE
Pharmacol Ther; 2019 Jun; 198():59-67. PubMed ID: 30790641
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
[TBL] [Abstract][Full Text] [Related]
3. Small molecule Mcl-1 inhibitors for the treatment of cancer.
Belmar J; Fesik SW
Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548
[TBL] [Abstract][Full Text] [Related]
4. MCL-1 inhibitors - where are we now (2019)?
Fletcher S
Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
[No Abstract] [Full Text] [Related]
5. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
[TBL] [Abstract][Full Text] [Related]
6. Mcl-1 inhibitors: a patent review.
Chen L; Fletcher S
Expert Opin Ther Pat; 2017 Feb; 27(2):163-178. PubMed ID: 27744724
[TBL] [Abstract][Full Text] [Related]
7. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
[TBL] [Abstract][Full Text] [Related]
8. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
[TBL] [Abstract][Full Text] [Related]
9. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract][Full Text] [Related]
10. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
12. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.
Yamaguchi R; Lartigue L; Perkins G
Pharmacol Ther; 2019 Mar; 195():13-20. PubMed ID: 30347215
[TBL] [Abstract][Full Text] [Related]
13. Development of Mcl-1 inhibitors for cancer therapy.
Negi A; Murphy PV
Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present).
Fan Y; Hou X; Fang H
Recent Pat Anticancer Drug Discov; 2020; 15(4):306-320. PubMed ID: 32938354
[TBL] [Abstract][Full Text] [Related]
15. Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.
Senichkin VV; Streletskaia AY; Zhivotovsky B; Kopeina GS
Trends Cell Biol; 2019 Jul; 29(7):549-562. PubMed ID: 31030977
[TBL] [Abstract][Full Text] [Related]
16. Targeting BCL-2-like Proteins to Kill Cancer Cells.
Cory S; Roberts AW; Colman PM; Adams JM
Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
[TBL] [Abstract][Full Text] [Related]
17. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
18. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.
Ashkenazi A; Fairbrother WJ; Leverson JD; Souers AJ
Nat Rev Drug Discov; 2017 Apr; 16(4):273-284. PubMed ID: 28209992
[TBL] [Abstract][Full Text] [Related]
19. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
[TBL] [Abstract][Full Text] [Related]
20. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
